Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Abstract Background The epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer has been successfully treated with tyrosine kinase inhibitors (TKIs). Acquired resistance becomes a tough issue when patients fail to respond to the third-generation TKI osimertinib. This stud...

Full description

Bibliographic Details
Main Authors: Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yunpeng Liu
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Cancer
Subjects:
Afatinib
EGFR
L718Q
Leptomeningeal metastasis
NSCLC
Online Access:http://link.springer.com/article/10.1186/s12885-019-5915-7

Internet

http://link.springer.com/article/10.1186/s12885-019-5915-7

Similar Items